The Reliance Trap: When Regulatory Strategy Becomes A Clinical Supply Problem

By Wilhelm van Zyl, Founder, Veltrion Laboratories

A global clinical team has several African countries under consideration for a study. The instinct is understandable. Prepare the dossiers, submit as broadly and as early as possible, and run the regulatory processes in parallel. More submissions should mean less delay.

On paper, that makes sense. Sometimes the opposite is true.

In markets where a regulator can take account of work already done elsewhere, the order of filing can matter almost as much as the quality of the file. The problem usually shows up later. Product has already been manufactured. Forecasts have been locked. A depot may have been contracted. Sites are approaching activation. The clinical team is asking why investigational product cannot move.

That is the reliance trap. Regulatory approval, importation, and clinical supply are treated as consecutive workstreams. They are one sequencing problem. An early filing decision can determine whether a faster pathway remains open, when product may legally enter the country, who may hold it, and when a site can dose.

These pages have already made the case that South Africa is underweighted in global supply planning. That point stands. Capability does not rescue a plan whose filing sequence has already closed the shorter path or started the manufacturing clock before anything can cross the border.

What Reliance Actually Changes

Reliance, for a supply team, is not a theory of African regulation. It is a narrower question. Can this country’s decision rest, in whole or in part, on work already done by another trusted authority, and what has to be true before that becomes useful?

SAHPRA’s published reliance guideline is a registration instrument. It allows an abridged, verified or, in time, recognized review of a marketing authorization application where the same product has already been approved by a recognized authority. The published list includes FDA, EMA, and MHRA, with further routes through WHO collaborative registration, ZAZIBONA, and the African Medicines Agency (AMA) continental listing. The product has to be the same product. The reference decision has to exist. If it does not, the application defaults to full review.

That is not a clinical trial rule. Sponsors who talk about using reliance to get a South African trial authorized faster are often describing the wrong instrument.

A trial has its own coordinated option in some programs. The African Vaccine Regulatory Forum joint review process exists so that national regulators and ethics committees can assess a common clinical trial application together. The regular process is built around a 60 working day window. It assumes a pre-submission discussion, then coordinated national filings. It is not designed around a scattering of independent submissions already running on separate clocks.

Importation is a third decision. In South Africa, Kenya, and Nigeria, investigational product may be imported only after the protocol has been authorized. What then sits on that authorization differs. South Africa treats the clinical trial approval letter as the import authority and needs the authorized quantity on the face of the letter. Kenya and Nigeria each issue a separate clinical trial import permit. In each case a named local party has to be entitled to receive the product before a depot can take custody of it.

None of this means that an African regulator will simply accept what the FDA accepted. It means a later decision can be shorter or cleaner if the earlier decision, the identity of the product, and the order of filing have been arranged to allow it.

Where The Apparently Rational Plan Breaks

The plan that files everywhere at once is trying to keep any one country off the critical path. That is where the difficulty starts.

If the shorter national route requires a reference decision, filing before that decision exists does not accelerate the country. It commits the application to a fuller review. SAHPRA’s guideline is explicit on the registration side. The product must already have been approved by a recognized authority, and the South African dossier must match the current approved product, including variations already incorporated abroad. File first and hope the foreign approval arrives later, and the abridged path is no longer the path you are on.

On the AMA continental listing route into South Africa the sequencing rule is sharper. SAHPRA’s February 2026 communication on that procedure is, again, a registration instrument. The distinction matters, and it should be kept. But the rule itself is the cleanest published example of the trap. An application may be submitted to SAHPRA on this pathway only after a positive AMA opinion has been issued. The opinion letter must travel with the file. The dossier must reflect any AMA conditions. Parallel submission to AMA and to SAHPRA is not accepted. SAHPRA says it will endeavor to finalize the evaluation and registration decision within 90 working days after screening has concluded. File nationally while the continental process is still running and you are not on that uptake path. You are on a different path, with a different clock.

A trial can lose the same kind of option even where no formal ban exists. AVAREF joint review is built on a common application and simultaneous national submission. A sponsor already running independent national reviews is not automatically barred from later cooperation. The coordinated process is simply harder to assemble around dossiers that are already live, diverging, or mid-query.

The useful question is not how quickly the first four dossiers can leave the building. It is what a submission in Country A does to the regulatory and supply options in Countries B, C, and D.

Follow The Product

That is where the regulatory question becomes a supply question.

Country selection decides which of these options even exist. A four-country protocol that includes one mature national review and three jurisdictions that can, in principle, take a coordinated or reliance-based decision is not four copies of the same workstream. Waiting for a reference decision can look like delay on a Gantt chart. Filing immediately can look like pace. The first may preserve a shorter national step and a cleaner import file. The second may consume shelf life while a full review runs.

Approval is the event that unlocks movement. In South Africa, investigational product may be imported only after SAHPRA has approved the protocol. Samples brought in before approval need a separate license. The clinical trial approval letter is, in practice, the import authority. SAHPRA has had to remind industry that those letters must specify authorized quantities, because border control cannot otherwise release the shipment. Where older letters are silent on quantity, a protocol amendment is required. That is not an administrative footnote. It is product sitting under customs control while the study team believes approval has already been obtained.

Kenya and Nigeria run the same logic on different paper. Kenya’s Pharmacy and Poisons Board authorization is what permits investigational product to enter or be manufactured in the country. A separate clinical trial import permit then rides on that authorization and on ethics clearance. NAFDAC will not allow investigational product into Nigeria until the trial has been authorized and an import permit stating quantities has been issued. A supply plan that assumes product can be staged in-country during review is assuming a legal fact that does not exist.

Who may hold the product is the next constraint. A global depot network does not become a lawful receiving party by being named in a vendor list. South Africa requires a local applicant for a foreign sponsor. Importation and wholesale dealing are licensed activities, and a responsible pharmacist sits on the manufacturing or wholesale license. Appoint the receiving party after the approval letter arrives and the letter cannot yet move boxes. The same logic applies in Kenya and Nigeria, on different licenses. The permit names who may bring the product in. It may be supplied only to the investigator and site named in that permit.

Labeling and allocation inherit all of this. Country-specific text, language, and importer particulars cannot be frozen until the receiving country and the receiving party are known. Global bulk and primary pack can often proceed. Country allocation, secondary pack, and shipment cannot, not if the alternative is a relabel, a quarantine, or a shipment that arrives before anyone is entitled to receive it.

Expiry is where the sequence becomes expensive. Product manufactured against an optimistic activation date consumes shelf life in storage and in query response. Forecasts built on a first-patient date that the import file cannot support produce a stockout or a second campaign of short-dated supply. Sites can be contractually ready and still unable to receive product.

Regulatory teams treat “filed” as progress. Supply teams treat “filed” as the date from which manufacturing, labeling, and depot contracts can proceed. In these markets the date that matters is not the filing date. It is the date on which importation becomes lawful and a named local party is entitled to receive the product.

South Africa Is Not The Region

South Africa is the market most global teams already treat as the African reference. That is rational. It is also why three different SAHPRA decisions get collapsed into one “approval,” and why the activation date then slips.

Reliance, as SAHPRA publishes it for medicines, is how a marketing-authorization application can be shortened because a recognized authority has already assessed the same product. Clinical trial authorization is a separate Clinical Trials Unit decision. Importation and custody sit at the port, and with the licensed parties who receive and distribute. The 2024 industry communication on quantity exists because an approval letter that does not say how much product may enter cannot be operated at the border.

A South African activation date is therefore not authorization plus two weeks for freight. It is authorization, a quantity-complete import authority, a licensed receiving party, and release against the approved protocol and the batch documentation. File the trial application before that construct exists and the approval arrives into a vacuum. File it as if it were a reliance registration file and the review team is being asked to do a job the guideline does not give them.

South Africa can still carry regional weight. The language of operations is English. Depot capacity exists. The regulator publishes its pathways. It cannot be copied, unexamined, into the next three countries on the protocol.

AVAREF joint review is available for some multi-country trials where the product meets the forum’s public health criteria. The scope is no longer limited to vaccines, but it is still not the standard path for every commercial study. AMA continental listing is a product mechanism. National authorities may take up a shared scientific opinion for registration. The listing does not replace national trial authorization. It does not authorize a depot to receive investigational product.

Kenya still splits board authorization, ethics clearance, a research permit, and a distinct import permit. Nigeria still splits NAFDAC trial authorization from a quantity-specific import permit. Language, label content, importer licensing, and the identity of the legal applicant differ with the country.

A design that assumes Johannesburg can feed Nairobi and Lagos on the same label, the same importer model, and the same approval-plus-freight calendar is not a regional design. It is a South African design with extra addresses.

Before The First File Leaves

Supply teams do not need a map of every African guideline. They need to answer five questions before the first dossier is sent.

1. Which jurisdictions could use reliance or joint review, and on what reference decision? Name the instrument. Registration reliance on an FDA or EMA approval is not the same as AVAREF joint review of a protocol, and neither is national uptake of an AMA listing. If the reference decision will not exist in time, do not plan as if the shorter path will.
2. Does filing now preserve that option or spend it? An early independent filing is the right move where no coordinated path exists. It is the wrong move where the value of waiting is a shared assessment, a matching dossier, or a reference approval that has not yet been issued.
3. What event actually unlocks importation in each country? In South Africa, Kenya, and Nigeria it is protocol authorization and, in Kenya and Nigeria, a separate import permit that states quantity. Submitted does not move product. Approved, with the right names and quantities on the letter, does.
4. Who must sit between the sponsor and the site? Applicant, importer, local representative, depot, pharmacist. Identify them before the trial application is filed. If the receiving party is not yet licensed for the activity, the approval cannot be used.
5. What is the latest sensible point to manufacture, label, allocate, and ship country-specific supply? Global bulk and primary pack can precede national certainty. Country allocation, secondary labeling, and shipment should wait on the event that makes receipt lawful or be accepted in advance as a risked inventory decision, with shelf life and relabel capacity priced in.

The fastest regulatory strategy is not always the one with the earliest first submission. It is the one that gets the right product, under the right authorization, into the right country and to the patient with the fewest avoidable dependencies. For teams taking studies into African markets, the filing sequence belongs upstream of shipment planning. It is part of how the supply chain is designed.

About The Author:

Wilhelm van Zyl is the founder of Veltrion Laboratories, based in Cape Town. Veltrion is a  regulatory affairs and market access consultancy for independent life sciences and healthcare specialists on African and Middle Eastern mandates. An admitted attorney of the High Court of South Africa, he previously served as associate director, global business operations at IQVIA and later worked at ICON on clinical trial contract infrastructure.

Contact: wilhelm@veltrionlaboratories.com; veltrionlaboratories.com